Inducible nitric oxide synthase neutralizes carbamoylating potential of 1,3-Bis(2-chloroethyl)-1-nitrosourea in C6 glioma cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 297, Issue 1, 2001, Pages 308-315

  Yin, J H ^a   Yang, D I ^a   Chou, H ^a   Thompson, E M ^a   Xu, J ^a   Hsu, C Y ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; LOMUSTINE; NITRIC OXIDE SYNTHASE; NITROSOUREA DERIVATIVE; TEMOZOLOMIDE;

ALKYLATION; ANIMAL CELL; ARTICLE; CANCER SURVIVAL; CELL KILLING; CHEMOSENSITIVITY; DRUG EFFECT; ENZYME INDUCTION; GLIOMA CELL; LIPOPHILICITY; NEOVASCULARIZATION (PATHOLOGY); NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTISENSE ELEMENTS (GENETICS); CARMUSTINE; DRUG RESISTANCE, NEOPLASM; GLIOMA; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RATS; TUMOR CELLS, CULTURED;

EID: 0035082476     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Glutathione content and glutathione-S-transferase expression in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines
2. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature
3. 1,3-Bis(2-chloroethyl)-1-nitrosourea as thiolcarbamoylating agent in biological systems
4. Chemosensitivity testing of human lung cancer cell lines using the MTT assay
5. The use of aminoguanidine, a selective iNOS inhibitor, to evaluate the role of nitric oxide in the development of autoimmune diabetes
6. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on surveillance, epidemiology, and end results (SEER) data, 1973-1991
7. Malignant glioma: Who benefits from adjuvant chemotherapy?
8. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA
9. Differential expression of inducible nitric oxide synthase mRNA in human brain tumors
10. Nitric oxide is an important mediator for tumoricidal activity in vivo
11. Induction of nitric oxide synthase in rat C6 glioma cells
12. The basis for current treatment recommendations for malignant gliomas
13. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
14. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma
15. Inducible nitric oxide synthase in a human glioblastoma cell line
16. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma
17. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluid
18. Expression of heme oxygenase and inducible nitric oxide synthase mRNA in human brain tumors
19. Differential modulation of chemosensitivity to alkylating agents and platinum compounds by DNA repair modulators in human lung cancer cell lines
20. Histopathology, classification and grading of gliomas
21. Nitric oxide synthase inhibition in migraine
22. Nitric oxide and macrophage function
23. Increased brain tumor microvessel permeability after intracarotid bradykinin is mediated by nitric oxide
24. Studies on the mechanism of decomposition and structural factors affecting the aqueous stability of 1,2-bis(sulfonyl)-1-alkylhydrazines
25. Comparison of DNA lesions produced by tumor-inhibitory 1,2- bis(sulfonyl)hydrazines and chloroethylnitrosoureas
26. Phase I evaluation of pre-irradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas
27. Dual inhibition of nitric oxide and prostaglandin production contributes to the anti-inflammatory properties of nitric oxide synthase inhibitors
28. 1,2-Bis(sulfonyl)hydrazines. 3. Effects of structural modification on antineoplastic activity
29. Synthesis and evaluation of 1,2,2-tris(sulfonyl)hydrazines as antineoplastic and trypanocidal agents
30. Synthesis and evaluation of 1-acyl-1,2-bis(methylsulfonyl)-2-(2-chloroethyl)hydrazines as antineoplastic agents
31. Antitumor 2-(aminocarbonyl)-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-hydrazines
32. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells
33. Effects of nitric oxide modulation on tumor blood flow and microvascular permeability in C6 glioma
34. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery
35. Interrelationships of some chemical, physicochemical, and biological activities of several 1-(2-haloethyl)-1-nitrosoureas
36. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages
37. Regulation of cytokine-induced iNOS expression by a hairpin oligonucleotide in murine cerebral endothelial cells
38. Involvement of de novo ceramide biosynthesis in tumor necrosis factor-α/ cycloheximide-induced cerebral endothelial cell death
39. Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity